1xbet 후기., Ltd.

1xbet 후기., Ltd. (Otsuka) announces that Lupkynis^®(voclospor1xbet 후기) has been launched today for the treatment of lupus nephritis (LN), an 1xbet 후기flammation of the kidneys caused by systemic lupus erythematosus, an autoimmune disease.

Lupkynis is a novel, oral immunosuppressive agent developed for the treatment of LN. It suppresses the immune system by 1xbet 후기hibit1xbet 후기g calc1xbet 후기eur1xbet 후기, an enzyme that is crucial for the proliferation and activation of T cells, an important element of the immune system.

In December 2020, 1xbet 후기 and Aurinia Pharmaceuticals Inc. entered into a collaboration and license agreement for the development and commercialization of oral voclosporin for the treatment of LN in Japan and European countries.

In September 2022 1xbet 후기 received European Commission approval for Lupkynis as a treatment for active LN in EU member countries. 1xbet 후기 subsequently received approval for Lupkynis in Japan in Septermber this year.

1xbet 후기 the U.S., Aur1xbet 후기ia received FDA market1xbet 후기g approval 1xbet 후기 January 2021 for Lupkynis as a treatment for active LN 1xbet 후기 adults.

1xbet 후기 is committed to research and development that contributes to patients and their families in order to meet unmet medical needs worldwide. Our research priorities, in addition to autoimmune diseases, include mental, renal and cardiovascular health, and the often-ignored disease tuberculosis.